Tags : or Unexplained

$Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough$

Clinical Trials

Merck Reports Results of Gefapixant (45mg) in Two P-III Studies

Tuba Khan September 9, 2020

Shots: The two P-III studies (COUGH-1 & -2) involves assessing of gefapixant (45/15mg, bid) vs PBO in 2,044 patients with refractory or unexplained chronic cough for 12 & 24wks. respectively […]readmore

Tags : or Unexplained

Merck Reports Results of Gefapixant (45mg) in Two P-III Studies

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : or Unexplained

Merck Reports Results of Gefapixant (45mg) in Two P-III Studies

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company